Name

Galaxy Brain Scientific

Legal name

Galaxy Brain Scientific Inc.

Website

https://gb-scientific.cn

Company type

Private

Founded year

2025

Operating status

Operating

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industries

Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices) (CRACAQAL), Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• Precision neuromodulation devices
• Brain circuit stimulation
• Non-invasive neural regulation
• Brain functional mapping
• Medical device therapy

Headquarters

HQ city

Beijing Shi

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales — Precision Brain Circuit Stimulation System: Sale of Class III precision brain circuit stimulation systems to hospitals and clinical institutions. The system is produced, commercialized, and deployed at leading hospitals including Beijing Tiantan Hospital, Peking University First Hospital, Henan Provincial People's Hospital, and Fujian Medical University Affiliated First Hospital. This is the primary revenue driver.
2. Clinical Services: Revenue generated through Galaxy Brain Medical's (银河脑医疗) own clinical service facilities in Beijing and Shanghai, providing direct patient treatment services using the precision brain circuit stimulation system. Hundreds of patients with stroke dysfunction, Parkinson's disease, Alzheimer's disease, and autism spectrum disorder have been treated.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Galaxy Brain Scientific develops and commercializes a Class III non-invasive Precision Brain Circuit Stimulation System (精准脑环路刺激系统) that delivers personalized neuromodulation based on its proprietary pBFS (personalized Brain Functional Sectors) brain functional mapping technology. The system is sold to top-tier hospitals and clinical institutions and is also deployed directly to patients through the company's own Galaxy Brain Medical (银河脑医疗) clinics in Beijing and Shanghai, targeting neurological disorders including Parkinson's disease, autism spectrum disorder, Alzheimer's disease, post-stroke cognitive and motor dysfunction, and treatment-resistant depression.

Differentiator

Problem solved

Functional benefit

Products and services

• Precision Brain Circuit Stimulation System (精准脑环路刺激系统) A Class III non-invasive neural regulation medical device based on pBFS technology. It delivers individualized, precise, non-invasive stimulation of neural circuits without requiring craniotomy surgery, treating brain dysfunction disorders including Parkinson's disease, autism, Alzheimer's, post-stroke dysfunction, and treatment-resistant depression. Deployed at 60+ hospitals across China.
• Galaxy Brain Medical Clinical Services (银河脑医疗) Direct-to-patient clinical services provided through wholly-owned subsidiary Galaxy Brain Medical (银河脑医疗) clinics in Beijing and Shanghai, delivering precision brain circuit stimulation treatment sessions to patients with Parkinson's disease, stroke dysfunction, Alzheimer's disease, autism spectrum disorder, and treatment-resistant depression. Over 3,000 clinical applications completed.

Quantifiable outcome

• Parkinson's disease treatment: >2x clinical efficacy improvement vs traditional stimulation targets using personalized SPARK circuit targeting
• +6 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Beijing University of Posts and Telecommunications (北京邮电大学)coreStrategic or Co-development Partner · 15 December 2025Collaboration led by Galaxy Brain Scientific, jointly with Capital Medical University Xuanwu Hospital, to develop the '脑功能环路引导的阿尔茨海默病闭环脑机接口治疗系统'. Professor Liu Yong's team at BUPT contributes expertise in brain imaging and AI platforms, building a multimodal large-scale database covering tens of thousands of cases for algorithmic training and intelligent processing of brain data.
• Capital Medical University Xuanwu Hospital (首都医科大学宣武医院)coreStrategic or Co-development Partner · 15 December 2025Collaboration led by Galaxy Brain Scientific, jointly with Beijing University of Posts and Telecommunications, to develop the Alzheimer's disease closed-loop brain-computer interface treatment system. Professor Tang Yi's team contributes clinical expertise in Alzheimer's intervention and cognitive assessment standards. As the National Neurological Disease Medical Center, Xuanwu Hospital provides clinical resources and a national collaboration network for product clinical verification and evaluation.
• Fujian Provincial Hospital / 福州大学附属省立医院minorStrategic or Co-development Partner · 15 December 2025Galaxy Brain Scientific participated in the construction of the '一少一老' brain disease medical AI database project led by Fujian Provincial Hospital. Galaxy Brain contributes its core technology in individual brain functional mapping and multi-dimensional brain data analysis. The database covers Parkinson's disease, Alzheimer's disease, stroke motor rehabilitation, and childhood autism diagnostic scenarios.

Scale indicators12 records

Recent moves6 records

Expansion highlights4 records

Regional players

• Ybrain: Ybrain is a Korean neuromodulation startup developing wearable TMS devices for depression and other neurological conditions. Regional peer to Galaxy Brain in the Asian non-invasive TMS market, addressing overlapping indications with smaller scale and limited geographic footprint compared to Galaxy Brain.

Direct peers

• MagVenture: MagVenture develops and markets TMS equipment used in clinical depression treatment and neuroscience research, with FDA-cleared systems for MDD. Competes with Galaxy Brain in the non-invasive neuromodulation device market, particularly for psychiatric and neurological indications.
• Neuronetics: Neuronetics develops NeuroStar, a non-invasive TMS system primarily for treatment-resistant depression, the most established commercial TMS player in the US. Galaxy Brain Scientific's iTBS-based precision brain circuit stimulation system competes in the same non-invasive neuromodulation category, targeting overlapping neurology indications including depression and movement disorders.
• Soterix Medical: Soterix Medical develops non-invasive brain stimulation and monitoring technologies including tDCS, tACS, and HD-tDCS systems used in research and clinical settings. Comparable to Galaxy Brain's precision non-invasive neuromodulation approach with emphasis on individualized targeting in neurology applications.
• Brainsway: Brainsway develops deep transcranial magnetic stimulation (dTMS) systems using H-coils for treatment-resistant depression, OCD, and other neurological indications. Comparable to Galaxy Brain's personalized targeting approach using non-invasive brain stimulation, with overlapping treatment indications and hospital sales model.
• Neuroelectrics: Neuroelectrics develops non-invasive transcranial electrical stimulation (tES/tDCS) devices with personalized EEG-based targeting for neurology and psychiatry applications. Highly comparable to Galaxy Brain's individualized brain-mapping-guided stimulation approach, both emphasizing precision targeting rather than one-size-fits-all protocols.
• Magstim: Magstim is a pioneer in TMS technology supplying research and clinical TMS systems globally. Sells transcranial magnetic stimulation devices used in both research and clinical applications including depression, making it a direct peer in the TMS equipment market where Galaxy Brain also competes.

Broad incumbents

• Abbott (Neuromodulation): Abbott's Neuromodulation division develops DBS and spinal cord stimulation devices including the Infinity DBS system for Parkinson's disease. Major incumbent in the implantable neuromodulation market that Galaxy Brain's non-invasive personalized stimulation system seeks to compete with as a less invasive alternative.
• Medtronic (Neuromodulation Division): Medtronic is the dominant player in implantable Deep Brain Stimulation (DBS) systems for Parkinson's disease, essential tremor, and dystonia. Galaxy Brain's non-invasive precision approach is positioned to disrupt Medtronic's DBS franchise by offering surgery-free alternative with personalized targeting, but Medtronic has vastly deeper clinical infrastructure and reimbursement expertise.

Emerging players

• Saluda Medical: Saluda Medical develops closed-loop neuromodulation systems including Evoke, a smart spinal cord stimulation system using real-time neural feedback. Comparable emerging player in the personalized/closed-loop neuromodulation space, with similar philosophy of measurement-guided individualized stimulation though applied to different indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galaxy Brain Scientific